Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).

Détails

Ressource 1Télécharger: 38756765.pdf (281.15 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_7689B1E13106
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
UNIL/CHUV
Titre
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
Périodique
Open forum infectious diseases
Auteur⸱e⸱s
Couchepin J., Reinhold I., Kronig I., Guidi M., Buclin T., Schreiber P.W., Neofytos D., Lamoth F.
Collaborateur⸱rice⸱s
Fungal Infection Network of Switzerland (FUNGINOS)
Contributeur⸱rice⸱s
Albrich W., Berezowska S., Berger C., Bergeron A., Bochud P.Y., Boggian K., Conen A., Emonet S., Erard V., Garzoni C., Goldenberger D., Hinic V., Hirzel C., Khanna N., Kohns M., Kronenberg A., Lamoth F., Landis B., Marchetti O., Mühlethaler K., Müller L., Neofytos D., Osthoff M., Pagani J.L., Quiblier C., Reinhold I., Riat A., Rupp N., Sanglard D., Schreiber P.W., Siegemund M., Walti L.
ISSN
2328-8957 (Print)
ISSN-L
2328-8957
Statut éditorial
Publié
Date de publication
05/2024
Peer-reviewed
Oui
Editeur⸱rice scientifique
Albrich W Berezowska S. Berger C. Bergeron A. Bochud P. Y. Boggian K. Conen A. Emonet S. Erard V. Garzoni C. Goldenberger D. Hinic V. Hirzel C. Khanna N. Kohns M. Kronenberg A. Lamoth F. Landis B. Marchetti O. Muhlethaler K. Muller L. Neofytos D. Osthoff M. Pagani J. L. Quiblier C. Reinhold I. Riat A. Rupp N. Sanglard D. Schreiber P. W. Siegemund M. Walti L., Fungal Infection Network of Switzerland
Volume
11
Numéro
5
Pages
ofae223
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.
Mots-clé
aspergillosis, hepatotoxicity, liver, mucormycosis, triazoles
URN
urn:nbn:ch:serval-BIB_7689B1E131066
OAI-PMH
oai:serval.unil.ch:BIB_7689B1E13106
DOI
10.1093/ofid/ofae223
Pubmed
38756765
Web of science
001224188900002
Open Access
Oui
Création de la notice
21/05/2024 14:31
Dernière modification de la notice
26/07/2024 7:02
Données d'usage